HSBC Securities downgraded Illumina from Buy to Hold and set a new price target of $100.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/12/2025 | $94.00 | Outperform → Neutral | Daiwa Securities |
| 7/11/2025 | $125.00 | Sector Outperform → Sector Perform | Scotiabank |
| 3/4/2025 | $130.00 → $90.00 | Neutral | Citigroup |
| 2/28/2025 | $100.00 | Buy → Hold | HSBC Securities |
| 2/10/2025 | $130.00 → $100.00 | Equal Weight → Underweight | Barclays |
| 2/7/2025 | $177.00 → $140.00 | Buy → Hold | TD Cowen |
| 12/11/2024 | $190.00 → $165.00 | Buy → Neutral | Citigroup |
| 11/12/2024 | $156.00 | Equal-Weight | Morgan Stanley |
4 - ILLUMINA, INC. (0001110803) (Issuer)
4 - ILLUMINA, INC. (0001110803) (Issuer)
4 - ILLUMINA, INC. (0001110803) (Issuer)
8-K - ILLUMINA, INC. (0001110803) (Filer)
8-K - ILLUMINA, INC. (0001110803) (Filer)
8-K - ILLUMINA, INC. (0001110803) (Filer)
Veteran genomics leader joins Illumina to advance global medical strategyIllumina chief commercial officer to depart for role as a life science tools company CEO SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Today, Illumina, Inc. (NASDAQ:ILMN) announced the appointment of Eric D. Green, M.D., Ph.D., as Chief Medical Officer (CMO), effective February 2. In this role reporting to the CEO, Dr. Green will accelerate the company's mission to drive a revolution in medicine by unlocking the power of the genome. Dr. Green will serve as a key scientific and medical leader representing Illumina, helping advance the clinical use of genomics, expand access to precision medicine solutions, and increase the di
Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham
Integrated software, AI-driven analytics, and frictionless workflows enable customers to harness the full power of biological insights SAN DIEGO, Jan. 6, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced the release of Illumina Connected Multiomics, a powerful cloud-based research software platform to analyze and visualize multiomic and multimodal biological data at scale. As multiomic datasets grow rapidly in size and complexity, researchers need easy-to-use tools to integrate information across transcriptomics, genomics, proteomics, epigenetics, and more. Connected Multiomics addresses this challenge by bringing multiomic data together in a single platform, reducing time, c
Daiwa Securities downgraded Illumina from Outperform to Neutral and set a new price target of $94.00
Scotiabank downgraded Illumina from Sector Outperform to Sector Perform and set a new price target of $125.00
Citigroup reiterated coverage of Illumina with a rating of Neutral and set a new price target of $90.00 from $130.00 previously
4 - ILLUMINA, INC. (0001110803) (Issuer)
4 - ILLUMINA, INC. (0001110803) (Issuer)
4 - ILLUMINA, INC. (0001110803) (Issuer)
Veteran genomics leader joins Illumina to advance global medical strategyIllumina chief commercial officer to depart for role as a life science tools company CEO SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Today, Illumina, Inc. (NASDAQ:ILMN) announced the appointment of Eric D. Green, M.D., Ph.D., as Chief Medical Officer (CMO), effective February 2. In this role reporting to the CEO, Dr. Green will accelerate the company's mission to drive a revolution in medicine by unlocking the power of the genome. Dr. Green will serve as a key scientific and medical leader representing Illumina, helping advance the clinical use of genomics, expand access to precision medicine solutions, and increase the di
Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham
Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as
Revenue of $1.08 billion for Q3 2025, flat compared to Q3 2024 on both a reported and constant currency basisGAAP operating margin of 21.0% and non-GAAP operating margin of 24.5% for Q3 2025GAAP diluted EPS of $0.98 and non-GAAP diluted EPS of $1.34 for Q3 2025Cash provided by operations of $284 million and free cash flow of $253 million for Q3 2025Repurchased 1.2 million shares of our common stock for $120 million at an average price of $97.10 per shareFor fiscal year 2025, we now expect:Total company constant currency revenue decline in the range of (1.5%) to (0.5%), up from (2.5%) to (1.5%)Revenue growth outside of China in the range of 0.5% - 1.5% on a constant currency basis, with no ch
SAN DIEGO, Oct. 14, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the third quarter 2025 following the close of market on Thursday, October 30, 2025. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call Details The conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, October 30, 2025. Interested parties may access the live webcast via the Investor Info section of Ill
Revenue of $1.06 billion for Q2 2025, down 3% from Q2 2024 on both a reported and constant currency basisGAAP operating margin of 20.2% and non-GAAP operating margin of 23.8% for Q2 2025GAAP diluted EPS of $1.49 and non-GAAP diluted EPS of $1.19 for Q2 2025Cash provided by operations of $234 million and free cash flow of $204 million for Q2 2025For fiscal year 2025, we now expect:Total company constant currency revenue decline in the range of (2.5%) to (0.5%), up from (3%) to (1%) previouslyNon-GAAP operating margin of approximately 22% - 22.5%, up from 21.5% - 22.0% previouslyNon-GAAP diluted EPS in the range of $4.45 - $4.55, an increase from our May guidance of $4.20 - $4.30. This include
SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)
SC 13G - ILLUMINA, INC. (0001110803) (Subject)
SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)